Advertisement

Topics

Synthetic Genomics, Inc Company Profile

07:12 EDT 19th September 2018 | BioPortfolio

Synthetic Genomics, Inc., a company founded by Dr. J. Craig Venter, is developing new scientific processes to enable industry to design and test desired genetic modifications. Using the genome as a bio-factory, a custom designed, modular “cassette” system will be developed so that the organism executes specific molecular functions. Synthetically produced organisms with reduced or reoriented metabolic needs will enable new, powerful, and more direct methods of bio-engineered industrial production.

Location

9601 Blackwell RoadSuite 200
Rockville
Maryland
20850
United States of America

Contact

Phone: 240.238.0800
Fax: 240.238.0888
Email: info@syntheticgenomics.com


News Articles [698 Associated News Articles listed on BioPortfolio]

Exxon, Synthetic Genomics partner for algae-derived biofuel production

Exxon Mobil and Synthetic Genomics will jointly develop biofuels made from algae that they have developed to produce twice as -More- 

ExxonMobil and Synthetic Genomics Scale up Algae Research

Following nearly 10 years of research, ExxonMobil and Synthetic Genomics are scaling up their joint research into using algae as a biofuel. The companies believe that 10,000 bbl/d of algae biofuel cou...

ExxonMobil and Synthetic Genomics Algae Biofuels Program Targets 10,000 Barrels Per Day by 2025

The post ExxonMobil and Synthetic Genomics Algae Biofuels Program Targets 10,000 Barrels Per Day by 2025 appeared first on SynBioBeta.

Freedom and flexibility: Thinking outside the cell for functional genomics

(DOE/Lawrence Berkeley National Laboratory) Along with advances in sequencing technologies and capacities, JGI has developed capabilities such as single-cell genomics, synthetic biology, and metabolom...

Life Sciences Industry Veteran Todd R. Nelson Named SGI-DNA CEO to Lead Spin-out from Synthetic Genomics

The post Life Sciences Industry Veteran Todd R. Nelson Named SGI-DNA CEO to Lead Spin-out from Synthetic Genomics appeared first on SynBioBeta.

Synthetic Genomics Appoints Reinhard J. Ambros, Ph.D., Former Global Head of the Novartis Venture Fund to Board of Directors

The post Synthetic Genomics Appoints Reinhard J. Ambros, Ph.D., Former Global Head of the Novartis Venture Fund to Board of Directors appeared first on SynBioBeta.

Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer

Phosphatase and tensin homolog (PTEN) is one of the most frequently inactivated tumor suppressors in breast cancer. While PTEN itself is not considered a druggable target, PTEN synthetic-sick or synth...

Synthetic Vaccines

In 2010 scientists from the JCVI announced the creation of the first bacterial cell controlled by a chemically synthesized genome1. The ‘synthetic’ cell was mycoplasma, a bacterium with an excepti...

PubMed Articles [763 Associated PubMed Articles listed on BioPortfolio]

Synthetic genomics: a new venture to dissect genome fundamentals and engineer new functions.

Since the first synthetic gene was synthesized in 1970s, the efficiency and the capacity of made-to-order DNA sequence synthesis has increased by several orders of magnitude. Advances in DNA synthesis...

Genome Writing: Current Progress and Related Applications.

The ultimate goal of synthetic biology is to build customized cells or organisms to meet specific industrial or medical needs. The most important part of the customized cell is a synthetic genome. Adv...

Synthetic drug use and HIV infection among men who have sex with men in China: A sixteen-city, cross-sectional survey.

Increasing evidence suggests an association between synthetic drug use and HIV infection among men who have sex with men (MSM). The aim of this study was to evaluate synthetic drug use prevalence, des...

Recent developments of software and database in microbial genomics and functional genomics.

Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.

Clinical Trials [431 Associated Clinical Trials listed on BioPortfolio]

CB1R in Synthetic Psychoactive Cannabinoids

The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoact...

Synthetic and Natural Caffeine on Hemodynamic Parameters in Young, Healthy Volunteers

The purpose of this study determine the difference in hemodynamic effects of synthetic and natural caffeine consumption in healthy individuals through blood pressure (central and periphera...

Natural Versus Synthetic Vitamin B Complexes in Human

In a cross-over study the investigators evaluate the effects of natural (Panmol-B-Complex) versus synthetic vitamin B complexes to identify the bioavailability of distinct vitamins as well...

Comparison Synthetic Hydroxyapatite and Inorganic Bovine Bone in Sinus Floor Elevation

This is set as prospective clinical trial to correlate histologically and radiologically the performance of four different bone grafts (synthetic hydroxyapatite alone, synthetic hydroxyapa...

Electronic Medical Records and Genomics (eMERGE) Phase III

The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clini...

Companies [640 Associated Companies listed on BioPortfolio]

Synthetic Genomics, Inc

Synthetic Genomics, Inc., a company founded by Dr. J. Craig Venter, is developing new scientific processes to enable industry to design and test desired genetic modifications. Using the genome as a bi...

Synthetic Genomics, Inc.

Synthetic Genomics, Inc., is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medi...

ERS Genomics and Cellecta

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for ...

Genomics in Business

In 2003 Keygene initiated the first edition of Genomics in Business. It was the first conference to focus on the existing and future applications of genomics in the Agro-Food industry. With participan...

Genomics One Corporation

Genomics One is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and mono-clonal antibodies. The mission...

More Information about "Synthetic Genomics, Inc" on BioPortfolio

We have published hundreds of Synthetic Genomics, Inc news stories on BioPortfolio along with dozens of Synthetic Genomics, Inc Clinical Trials and PubMed Articles about Synthetic Genomics, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Synthetic Genomics, Inc Companies in our database. You can also find out about relevant Synthetic Genomics, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record